- Home
- CLLS vs NCZ Comparison
CLLS vs NCZ Comparison
Compare CLLS & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- NCZ
- Stock Information
- Founded
- CLLS 1999
- NCZ 2003
- Country
- CLLS France
- NCZ United States
- Employees
- CLLS N/A
- NCZ N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- NCZ Finance Companies
- Sector
- CLLS Health Care
- NCZ Finance
- Exchange
- CLLS Nasdaq
- NCZ Nasdaq
- Market Cap
- CLLS 143.4M
- NCZ 228.3M
- IPO Year
- CLLS 2007
- NCZ N/A
- Fundamental
- Price
- CLLS $1.59
- NCZ $12.99
- Analyst Decision
- CLLS Buy
- NCZ
- Analyst Count
- CLLS 1
- NCZ 0
- Target Price
- CLLS $4.00
- NCZ N/A
- AVG Volume (30 Days)
- CLLS 48.2K
- NCZ 533.0K
- Earning Date
- CLLS 08-05-2025
- NCZ 01-01-0001
- Dividend Yield
- CLLS N/A
- NCZ 12.16%
- EPS Growth
- CLLS N/A
- NCZ N/A
- EPS
- CLLS N/A
- NCZ N/A
- Revenue
- CLLS $54,747,000.00
- NCZ N/A
- Revenue This Year
- CLLS $48.52
- NCZ N/A
- Revenue Next Year
- CLLS $5.17
- NCZ N/A
- P/E Ratio
- CLLS N/A
- NCZ N/A
- Revenue Growth
- CLLS 351.26
- NCZ N/A
- 52 Week Low
- CLLS $1.10
- NCZ $2.50
- 52 Week High
- CLLS $2.43
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- NCZ 75.05
- Support Level
- CLLS $1.56
- NCZ $12.78
- Resistance Level
- CLLS $1.49
- NCZ $12.95
- Average True Range (ATR)
- CLLS 0.09
- NCZ 0.14
- MACD
- CLLS 0.01
- NCZ 0.02
- Stochastic Oscillator
- CLLS 80.00
- NCZ 97.56
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.